Veracyte Inc VCYT:NASDAQ

Last Price$23.62Cboe Real-Time Last Sale as of 11:24AM ET 11/12/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.14(0.60%)
Bid (Size)$23.45 (100)
Ask (Size)$23.59 (300)
Day Low / High$23.46 - 24.15
Volume75.3 K

Veracyte Says Cancer Cytopathology Details Co.'s Role in Reducing 'Unnecessary' Surgeries in Thyroid Cancer Diagnosis

2:56PM ET 6/17/2019 MT Newswires
Veracyte (VCYT) said Monday a review article in Cancer Cytopathology, a journal of the American Cancer Society, describes how the technology behind Veracyte's Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) is helping reduce "unnecessary surgeries in thyroid cancer diagnosis."

The company said its products are also informing surgery and treatment decision-making using the same minimally invasive patient sample, according to a statement.

"Our RNA platform uniquely enables our Afirma offering to answer important clinical questions that can guide various points in a patient's journey, helping to improve outcomes," CEO Bonnie Anderson said. "Further, by providing this comprehensive information from the original biopsy used in diagnosis, we can streamline workflows and enable patients to get the answers they need faster and more easily."

Shares rose by more than 3% intraday.

Price: 28.42, Change: +0.85, Percent Change: +3.10